Xifaxan Ibsd denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xifaxan ibsd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Issue a "Not FDA-Approved" Denial for Xifaxan in IBS-D — and Why It Is Appealable

This denial category can arise in two scenarios. First, a coding or administrative error may have caused UHC's system to process the claim as an off-label or unapproved use, when in fact the FDA has approved Xifaxan (rifaximin) for IBS-D in non-constipation-predominant adults. Second, the denial may reflect a misread of the diagnosis code submitted — for example, if the submitted ICD-10 code did not clearly align with the FDA-approved indication. Either way, this denial type is among the most straightforward to overturn because the FDA approval record is publicly verifiable.

## Your Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal immediately. Include the FDA approval documentation directly in your submission.
• External review: If the internal appeal is denied, an independent reviewer — not UHC — will evaluate the claim. External review decisions are binding on the insurer. File within the four-month window from the final internal denial.
• Expedited review: Request expedited processing if the denial is delaying urgent or ongoing treatment.

## Documentation to Gather

1. FDA approval confirmation — download or print the FDA prescribing label for Xifaxan (rifaximin) and highlight the section confirming approval for IBS-D. The FDA's Drugs@FDA database is the authoritative public source. 2. Diagnosis documentation — chart notes and the ICD-10 code used on the claim; confirm the code reflects IBS-D and aligns with the FDA-approved indication language. 3. Claim submission records — a copy of the original claim, the EOB, and the denial letter, so you can identify whether the denial stems from a coding mismatch or a substantive coverage dispute. 4. Prescriber letter — the prescriber should confirm the diagnosis, affirm the on-label nature of the prescription, and request that UHC correct the record. 5. UHC coverage policy — obtain UHC's published policy for Xifaxan to verify whether the denial is a coverage rule or an administrative error.

## Criteria-Mapping Structure

| Denial Basis | Your Rebuttal Document | |---|---| | Drug not FDA-approved for condition | FDA label (Drugs@FDA), IBS-D indication highlighted | | Diagnosis code mismatch | Corrected claim with accurate ICD-10 code, prescriber confirmation | | Coverage policy exclusion | UHC policy text vs. FDA label, mapped side by side |

If the denial was purely administrative (wrong code processed), a peer-to-peer call between the prescriber and UHC's medical director may resolve the issue before a formal appeal is necessary.